Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 15, 2026

Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening

View original at finance.yahoo.com
Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening Paramount Television Studios Has Leased 70,000 Square Feet for Filming Season Two of the Hit Showtime® Original Series NEW YORK, January 15, 2026--(BUSINESS WIRE)--Today, Vornado Realty Trust (N…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Paramount Television Studios is thrilled to bring the second season of Dexter: Resurrection to Sunset Pier 94 Studios and its state-of-the-art facilities and sound stages

    80% confidence

  • Sunset Pier 94 Studios is expected to create 400 permanent jobs and contribute $6.4 billion to the local economy over the next 30 years

    80% confidence

  • Sunset Studios' success in attracting and retaining top-tier productions across multiple seasons speaks to the caliber of studios and services

    80% confidence

  • Last season saw Dexter move to New York City and now the production will follow suit, gaining greater access to the region's incredible creative talent

    80% confidence

  • Robust pre-leasing interest in Sunset Pier 94 Studios underscores the project's unmatched quality and prime location with nothing else like it in the market

    80% confidence

  • Season one of Dexter: Resurrection was filmed in New York, generating significant economic impact in neighborhoods through jobs and small business spending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com